<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588171</url>
  </required_header>
  <id_info>
    <org_study_id>Hawler Medical University</org_study_id>
    <nct_id>NCT01588171</nct_id>
  </id_info>
  <brief_title>Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum</brief_title>
  <official_title>Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hawler Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hawler Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of a new generation low molecular weight heparin (Bemiparin)and the well known LMWH
      (Enoxaparin) after Caesarean sections and vaginal deliveries in a risky group patients for
      venous thrombosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous thromboembolism (VTE) is the leading cause of maternal mortality and morbidity in the
      developed and developing world. Pulmonary embolism and deep vein thrombosis are the two
      components of a single disease called deep vein thrombosis (DVT). Pregnancy associated with
      an average 5 to 10 fold increase in the risk of VTE compared with non-pregnant women. The
      highest incidence occurring during the post partum period. There are many researches done a
      broad on the effect of LMWH to decrease the incidence of VTE after Caesarean section using
      the two LMWH (Enoxaparin and Bemiparin) alone but not in one research comparing both of them
      alone and both together against a control group. Also according to our knowledge there are no
      published literature on thromboprophylaxis after vaginal delivery
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism</measure>
    <time_frame>40 days after delivery</time_frame>
    <description>compare two low molecular weight heparin (Bemiparin versus Enoxaparin) after delivery with non receiver participant for development of venous thromboembolic diseases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>after receiving the injections and till 40 days</time_frame>
    <description>bruising or pain at the site of injection,Bleeding,allergic skin reactions, itching, urticaria,wound hematoma, separation, or dehiscence</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7020</enrollment>
  <condition>Venous Thromboembolic Diseases</condition>
  <arm_group>
    <arm_group_label>Bemiparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A new second generation Low Molecular Weight Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A well known Low Molecular Weight Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Risky group patients for VTE, but they will not receive any thromboprophylactic drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemiparin</intervention_name>
    <description>Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.</description>
    <arm_group_label>Bemiparin</arm_group_label>
    <other_name>Hibor; Laboratories Rovi Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.</description>
    <arm_group_label>Bemiparin</arm_group_label>
    <arm_group_label>Enoxaparin</arm_group_label>
    <other_name>Clexane(Sanofi aventis)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of risk factors for venous thromboembolism

          -  Any parity

          -  Mode of delivery:vaginal, Emergency and Elective Caesarean section

          -  No any contraindications for Heparin

        Exclusion Criteria:

          -  Active antenatal or postpartum vaginal bleeding.

          -  Placenta previa

          -  Thrombocytopenia

          -  Sever renal or liver diseases

          -  Uncontrolled sever hypertension

          -  Any patient who is already on Heparin during pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shahla K. Alalaf, Ass.Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hawler Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rojan K. Jawad, High Diploma</last_name>
    <role>Study Chair</role>
    <affiliation>Hawler Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Parez R. Muhammad, High Diploma</last_name>
    <role>Study Chair</role>
    <affiliation>Hawler Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahabad S. Ali, High Diploma</last_name>
    <role>Study Chair</role>
    <affiliation>Hawler ministry of Health, Directorate of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Namir G. Al Tawil, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Hawler Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hawler medical university</name>
      <address>
        <city>Erbil city</city>
        <state>Kurdistan region</state>
        <zip>383-65</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawler medical university</name>
      <address>
        <city>Erbil</city>
        <state>Kurdistan region</state>
        <zip>383-65</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hawler Medical University</investigator_affiliation>
    <investigator_full_name>Assistant Prof. Shahla Alalaf</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Deep vein thrombosis</keyword>
  <keyword>Pulmonary embolism</keyword>
  <keyword>Low molecular weight heparin</keyword>
  <keyword>Enoxaparin</keyword>
  <keyword>Bemiparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

